Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone
2024 ASCO Annual Meeting
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We're presenting data on the durability of clinical complete responses in mismatch repair-deficient locally advanced rectal cancer to PD-1 therapy alone. We designed a phase II clinical trial of neoadjuvant PD-1 blockade with dostarlimab in mismatch repair-deficient rectal cancer, with the idea that we could use immunotherapy alone, dostarlimab alone to treat locally advanced rectal cancer, and potentially omit standard approaches to therapy, including chemotherapy, radiation, and surgery. And we initially presented the data two years ago. In June of 2022, we noted complete responses, 100% complete responses in 14 consecutive patients. So now we're presenting the expanded data. The trial has been ongoing, and we continue to see a hundred percent complete clinical responses now in 42 patients treated with dostarlimab.
None of our patients have needed chemotherapy, radiation, or surgery. The second primary endpoint of the trial was the durability of these complete responses. And we have seen now that 24 patients have had more than a year of complete clinical responses after completion of dostarlimab. Really showing that not only are we seeing 100% complete responses, but that these responses are in fact durable in patients. And in terms of quality of life, this has been incredibly impactful for patients. None have needed chemotherapy, radiation, or surgery. And we've seen very little toxicity, only grade 1 or 2 toxicity on trial to dostarlimab, so the patient's quality of life is maintained after treatment.
There is now a global study called AZUR-1 with the same exact design, looking at neoadjuvant therapy with dostarlimab in mismatch repair-deficient rectal cancer. Which is a registration study that will hopefully provide care to all patients with early-stage mismatch repair-deficient rectal cancer, and change the standard of care in this population.
Related Videos
The ASCO Post Staff
Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).
The ASCO Post Staff
Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).
The ASCO Post Staff
Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).
The ASCO Post Staff
Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).